Tekmira wins $2.4 million NIH grant

Tekmira Pharmaceuticals (TSX:TKM) and its collaborators at the University of Texas Medical Branch at Galveston, Tex. have received a $2.4 million (U.S.) grant from the U.S. National Institutes of Health to support research to develop RNAi therapeutics to treat Ebola and Marburg hemorrhagic fever viral infections using Tekmira’s lipid nanoparticle delivery technology. According to a [...]

Tekmira and Bristol-Myers in validation program

Tekmira Pharmaceuticals (TSX:TKM) has signed a four-year agreement with Bristol-Myers Squibb (NYSE:BMY) to validate certain cellular targets using its stable nucleic acid-lipid particles (SNALP) technology in exchange for an upfront payment of $3 million (U.S.). Under the agreement, Bristol-Myers Squibb will use RNA interfering molecules formulated by Tekmira in SNALP to silence target genes of [...]

Tekmira’s leading RNAi platform ready for prime time

As a global leader in the emerging field of RNA interference (RNAi), which holds the potential of revolutionizing medicine with new therapeutics, upstart Tekmira Pharmaceuticals (TSX:TKM) is at the precipice of confirming that the highly touted science works in humans. “We really are at the crux,” CEO Dr. Mark Murray says in an exclusive interview [...]